ABOUT US

BIOHYL

BIOHYL & OSTEOARTHRITIS

ABOUT HYALURONAN

CONTACT

BIOHYL™ & OSTEOARTHRITIS

University of Western Ontario researchers recently concluded that BioHyl™ maintains healthy joints.  In a preclinical investigation BioHyl™ was shown to slow the progress of osteoarthritis, protect articular cartilage, and prevent osteophytes in an aggressive osteoarthritis model, (Welch 2007). 
Osteoarthritis is the most common joint disorder.  The chronic disease is characterized by a progressive loss of the joint cushioning articular cartilage of synovial joints.  It can also cause concomitant bony changes; including sclerosis and osteophyte (spur) formation.  In the case of osteoarthritis, joint health can be assessed objectively by a histopathological grading and staging scale. The Osteoarthritis Research Society International Working Group has established an assessment system with metrics reflecting both the depth of the progression of osteoarthritis into articular cartilage and the extent of the surface of the cartilage that is involved (Pritzker et al 2006).
The effect of BioHyl's oral biopolymer in preventing the progression of osteoarthritis and preserving the surface of articular cartilage was dramatic.  Neither any competing supplement ingredient nor any anti-inflammatory drug has been shown to have a similar effect.

Saline Control Group	BioHyl Treatment Group
Sagittal section of stifle (knee)  joint 5 weeks post-ACL resection showing complete denudation of cartilage and formation of osteophytes.	Sagittal section of stifle (knee)  joint 5 weeks post-ACL resection showing healthy cartilage.

BioHyl helps people

A study of 42 subjects with various levels of discomfort in the joints, neck, and back was conducted to identify benefits conferred by daily use.  Subjects in the study, performed under the supervision of Douglas W. Kiburz, M.D., FAAOS presented for orthopedic evaluation but were not candidates for immediate surgery.  Over 80% of subjects experienced clinically meaningful benefit from daily use as directed with no serious adverse events reported. (Kiburz 2007). 

References
Kiburz DW (2007). Manuscript in preparation.
Pritzker, K.P.H. et al., Osteoarthritis and Cartilage 14, 13 (2006) 
Welch I (2007). Manuscript in preparation.

Compiled by G.D. McClure Jr., Ph.D., Chief Scientific Officer,
Cogent Solutions Group.

OUR PRODUCTS
CONTAINING BIOHYL

BAXYL SITE
RUNOVIA
TRIXSYN